FR2808803B1
(en)
*
|
2000-05-11 |
2004-12-10 |
Agronomique Inst Nat Rech |
MODIFIED ES CELLS AND SPECIFIC GENE OF ES CELLS
|
WO2002097090A1
(en)
*
|
2001-05-31 |
2002-12-05 |
Sumitomo Pharmaceuticals Co., Ltd. |
Genes with es cell-specific expression
|
CN101365480B
(en)
|
2005-11-01 |
2014-11-05 |
诺华疫苗和诊断有限两合公司 |
Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
|
US20090220541A1
(en)
|
2005-11-04 |
2009-09-03 |
Novartis Vaccines And Diagnostics Srl |
Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
|
JP2009514850A
(en)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
DK2368572T3
(en)
|
2005-11-04 |
2020-05-25 |
Seqirus Uk Ltd |
Adjuvant vaccines with non-virion antigens produced from influenza viruses grown in cell culture
|
PT1951299E
(en)
|
2005-11-04 |
2012-02-28 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
NZ592713A
(en)
|
2005-11-04 |
2012-12-21 |
Novartis Vaccines & Diagnostic |
Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
|
EP2478916B1
(en)
|
2006-01-27 |
2020-04-01 |
Seqirus UK Limited |
Influenza vaccines containing hemagglutinin and matrix proteins
|
EP2382987A1
(en)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Storage of influenza vaccines without refrigeration
|
FR2898909A1
(en)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Combination of markers to characterize avian cells of StX cells, germinal cells or stem cells, comprises markers of a target gene expressed in the StX cells, stem cells or in the germinal cells
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
CN101553252A
(en)
|
2006-12-06 |
2009-10-07 |
诺华有限公司 |
Vaccines including antigen from four strains of influenza virus
|
NZ582595A
(en)
|
2007-06-27 |
2012-07-27 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
AU2009227674C1
(en)
|
2008-03-18 |
2015-01-29 |
Seqirus UK Limited |
Improvements in preparation of influenza virus vaccine antigens
|
WO2010079081A1
(en)
|
2009-01-07 |
2010-07-15 |
Glaxosmithkline Biologicals S.A. |
Methods for recovering a virus or a viral antigen produced by cell culture
|
JP5843615B2
(en)
|
2009-02-06 |
2016-01-13 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Purification of viruses or viral antigens by density gradient ultracentrifugation
|
CA2752039A1
(en)
|
2009-02-10 |
2010-08-19 |
Novartis Ag |
Influenza vaccine regimens for pandemic-associated strains
|
EP2396031A1
(en)
|
2009-02-10 |
2011-12-21 |
Novartis AG |
Influenza vaccines with increased amounts of h3 antigen
|
DK2396032T3
(en)
|
2009-02-10 |
2016-12-19 |
Seqirus Uk Ltd |
Influenza vaccines with reduced amounts of squalene
|
FR2949344A1
(en)
|
2009-04-27 |
2011-03-04 |
Novartis Ag |
FLU PROTECTIVE VACCINES
|
AU2010293902A1
(en)
|
2009-09-10 |
2012-03-22 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
WO2011095596A1
(en)
|
2010-02-04 |
2011-08-11 |
Vivalis |
Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
|
EP2545172B2
(en)
|
2010-03-08 |
2017-12-06 |
Novartis AG |
Methods of testing for intracellular pathogens
|
CA2797059A1
(en)
|
2010-05-03 |
2011-11-10 |
Glaxosmithkline Biologicals S.A. |
Novel method
|
KR20130079398A
(en)
|
2010-05-06 |
2013-07-10 |
노파르티스 아게 |
Organic peroxide compounds for microorganism inactivation
|
AU2011254204B2
(en)
|
2010-05-21 |
2015-08-20 |
Seqirus UK Limited |
Influenza virus reassortment method
|
KR20130081659A
(en)
|
2010-06-01 |
2013-07-17 |
노파르티스 아게 |
Concentration of vaccine antigens with lyophilization
|
PT2575872T
(en)
|
2010-06-01 |
2020-11-19 |
Seqirus Uk Ltd |
Concentration of influenza vaccine antigens without lyophilization
|
WO2012023044A1
(en)
|
2010-08-20 |
2012-02-23 |
Novartis Ag |
Soluble needle arrays for delivery of influenza vaccines
|
WO2013000982A1
(en)
|
2011-06-27 |
2013-01-03 |
Vivalis |
Method for screening cells
|
GB201216121D0
(en)
|
2012-09-10 |
2012-10-24 |
Novartis Ag |
Sample quantification by disc centrifugation
|
AU2012324398A1
(en)
|
2011-10-20 |
2014-05-01 |
Seqirus UK Limited |
Adjuvanted influenza B virus vaccines for pediatric priming
|
GB201218195D0
(en)
|
2012-10-10 |
2012-11-21 |
Istituto Zooprofilattico Sperimentale Delle Venezie |
Composition
|
BE1022132B1
(en)
|
2013-08-30 |
2016-02-19 |
Glaxosmithkline Biologicals S.A. |
NEW METHOD.
|
ES2721535T3
(en)
|
2014-12-16 |
2019-08-01 |
Glaxosmithkline Biologicals Sa |
Large-scale virus purification procedure
|
PT3233130T
(en)
|
2014-12-17 |
2021-06-24 |
Fundacion Para La Investig Medica Aplicada |
Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease
|
PT3233129T
(en)
|
2014-12-17 |
2020-04-15 |
Fundacion Para La Investig Medica Aplicada |
Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
|
WO2016207853A2
(en)
|
2015-06-26 |
2016-12-29 |
Seqirus UK Limited |
Antigenically matched influenza vaccines
|
AU2016290603B2
(en)
|
2015-07-07 |
2022-06-02 |
Seqirus UK Limited |
Influenza potency assays
|
EP3794127A1
(en)
|
2018-05-14 |
2021-03-24 |
Vivet Therapeutics |
Gene therapy vectors comprising s/mar sequences
|
MX2021004154A
(en)
|
2018-10-12 |
2021-08-05 |
Vivet Therapeutics |
Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3).
|
CA3118936A1
(en)
|
2018-11-16 |
2020-05-22 |
Encoded Therapeutics, Inc. |
Compositions and methods for treating wilson's disease
|
CA3145446A1
(en)
|
2019-07-02 |
2021-01-07 |
Fundacion Para La Investigacion Medica Aplicada |
Cpla2e inducing agents and uses thereof
|
CN115380107A
(en)
|
2019-11-18 |
2022-11-22 |
思齐乐私人有限公司 |
Method for producing reassortant influenza viruses
|
CA3181024A1
(en)
|
2020-08-06 |
2022-02-10 |
Fundacion Para La Investigacion Medica Aplicada |
Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
|
US20230265456A1
(en)
|
2020-08-10 |
2023-08-24 |
Fundacion Para La Investigacion Medica Aplicada |
Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
|
PE20230987A1
(en)
|
2020-10-09 |
2023-06-21 |
UCB Biopharma SRL |
NUCLEIC ACID CONSTRUCTS, VIRAL VECTORS AND VIRAL PARTICLES
|
AU2022378524A1
(en)
|
2021-10-28 |
2024-05-02 |
UCB Biopharma SRL |
Nucleic acid constructs, viral vectors and viral particles
|